Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus
Open Access
- 25 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetology & Metabolic Syndrome
- Vol. 13 (1), 1-6
- https://doi.org/10.1186/s13098-021-00652-5
Abstract
Asprosin, a novel adipokine that raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM. This study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI) ≥ 23.0 kg/m2 and haemoglobin A1c (HbA1c) levels of 58–85 mmol/mol (7.5–10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n = 19) or placebo (n = 10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. Besides, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and 24 weeks. At 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P < 0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG, and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P < 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in the SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment. These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system. Trial registration CTR20131268; Registered 20 March 2014 CTR20150102; Registered 03 March 2015. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.Keywords
Other Versions
Funding Information
- the Jiangsu Natural Science Foundation (BK20171121)
- the Nanjing Medical Science and Technique Development Foundation (YKK18230)
This publication has 30 references indexed in Scilit:
- The role of Asprosin in patients with dilated cardiomyopathyBMC Cardiovascular Disorders, 2020
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020Diabetes Care, 2019
- Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathwayLife Sciences, 2019
- A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: AsprosinThe American Journal of Emergency Medicine, 2018
- IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045Diabetes Research and Clinical Practice, 2018
- Asprosin is a centrally acting orexigenic hormoneNature Medicine, 2017
- Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglycerideClinica Chimica Acta; International Journal of Clinical Chemistry, 2017
- Asprosin, a Fasting-Induced Glucogenic Protein HormoneCell, 2016
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes MellitusAnnual Review of Medicine, 2015
- Mechanisms linking obesity with cardiovascular diseaseNature, 2006